3-bromomethyl-1-azaanthraquinone | 177158-02-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 3-bromomethyl-1-azaanthraquinone
• 英文别名: 3-(Bromomethyl)benzo[g]quinoline-5,10-dione
• CAS: 177158-02-0
• 化学式: C₁₄H₈BrNO₂
• 分子量: 302.127
• InChiKey: YHKOEEJDKXKGEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  47
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-bromomethyl-1-azaanthraquinone 在 lithium hydroxide 、 三乙胺 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (5,10-dioxobenzo[g]quinolin-3-yl)methyl N-phenylcarbamate
  参考文献：
  名称：

  Synthesis and in vitro evaluation of 3-substituted-1-azaanthraquinones

  摘要：

  In the course of developing novel antitumor agents, we synthesized 3-substituted-1-azaanthraquinones, incorporating the alkylating or latent alkylating substituents as potential antitumor agents. The most active comound 4 exhibited cytotoxic activity comparable to that of doxorubicin. The compounds 3-8 retained much of their activity against the doxorubicin-resistant cell line (MCF7/R). Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00156-4
• 作为产物：
  描述：

  3-methylbenzo[g]quinoline-5,10-dione 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 作用下， 以 二氯甲烷 为溶剂， 以36%的产率得到3-bromomethyl-1-azaanthraquinone
  参考文献：
  名称：

  Synthesis and in vitro evaluation of 3-substituted-1-azaanthraquinones

  摘要：

  In the course of developing novel antitumor agents, we synthesized 3-substituted-1-azaanthraquinones, incorporating the alkylating or latent alkylating substituents as potential antitumor agents. The most active comound 4 exhibited cytotoxic activity comparable to that of doxorubicin. The compounds 3-8 retained much of their activity against the doxorubicin-resistant cell line (MCF7/R). Copyright (C) 1996 Elsevier Science Ltd

  DOI：

  10.1016/0960-894x(96)00156-4

文献信息

• [EN] HETEROCYCLIC NAPHTHOQUINONES DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INCLUDING CUSHING DISEASE<br/>[FR] DÉRIVÉS DE NAPHTHOQUINONES HÉTÉROCYCLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE CANCERS, Y COMPRIS LA MALADIE DE CUSHING
  申请人：COMMISSARIAT ENERGIE ATOMIQUE

  公开号：WO2018029137A1

  公开（公告）日：2018-02-15

  The present invention concerns heterocyclic naphthoquinones derivatives for use in the treatment of Cushing disease and other cancers, in particular via the inhibition of Ubiquitin Specific Proteases (USP) 8 and/or 2.

  本发明涉及杂环萘醌衍生物，用于治疗Cushing病和其他癌症，特别是通过抑制泛素特异性蛋白酶（USP）8和/或2来实现。
• HETEROCYCLIC NAPHTHOQUINONES DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INCLUDING CUSHING DISEASE
  申请人：Commissariat à l'Énergie Atomique et aux Énergies Alternatives

  公开号：EP3497083B1

  公开（公告）日：2022-01-19
• Heterocyclic Naphthoquinones Derivatives for Use in the Treatment of Cancers Including Cushing Disease
  申请人：Commissariat a l'Energie Atomique et aux Energies Alternatives

  公开号：US20190169136A1

  公开（公告）日：2019-06-06

  The present invention concerns heterocyclic naphthoquinones derivatives for use in the treatment of Cushing disease and other cancers, in particular via the inhibition of Ubiquitin Specific Proteases (USP) 8 and/or 2.
• Synthesis and in vitro evaluation of 3-substituted-1-azaanthraquinones
  作者：Heesoon Lee、Seoung-Soo Hong、Young-Ho Kim

  DOI：10.1016/0960-894x(96)00156-4

  日期：1996.4

  In the course of developing novel antitumor agents, we synthesized 3-substituted-1-azaanthraquinones, incorporating the alkylating or latent alkylating substituents as potential antitumor agents. The most active comound 4 exhibited cytotoxic activity comparable to that of doxorubicin. The compounds 3-8 retained much of their activity against the doxorubicin-resistant cell line (MCF7/R). Copyright (C) 1996 Elsevier Science Ltd